These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 12112937)

  • 21. Insulin therapy for patients with type 1 diabetes.
    Bhatia E; Aggarwal A
    J Assoc Physicians India; 2007 Jul; 55 Suppl():29-34, 39-40. PubMed ID: 17927009
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The current aspects of the pharmacological correction of hyperglycemia in patients with non-insulin-dependent diabetes mellitus (type 2)].
    Gorbenko NI
    Eksp Klin Farmakol; 1999; 62(5):71-8. PubMed ID: 10572759
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Practical approaches to insulin therapy.
    Gavin JR
    Diabetes Educ; 2007; 33 Suppl 3():66S-73S. PubMed ID: 17426310
    [No Abstract]   [Full Text] [Related]  

  • 24. Impairment of GLP1-induced insulin secretion: role of genetic background, insulin resistance and hyperglycaemia.
    Herzberg-Schäfer S; Heni M; Stefan N; Häring HU; Fritsche A
    Diabetes Obes Metab; 2012 Oct; 14 Suppl 3():85-90. PubMed ID: 22928568
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current role of short-term intensive insulin strategies in newly diagnosed type 2 diabetes.
    Xu W; Weng J
    J Diabetes; 2013 Sep; 5(3):268-74. PubMed ID: 23551748
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Unresolved challenges with insulin therapy in type 1 and type 2 diabetes: potential benefit of replacing amylin, a second beta-cell hormone.
    Edelman SV; Weyer C
    Diabetes Technol Ther; 2002; 4(2):175-89. PubMed ID: 12079621
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High normal 2-hour plasma glucose is associated with insulin sensitivity and secretion that may predispose to type 2 diabetes.
    Piché ME; Lemieux S; Pérusse L; Weisnagel SJ
    Diabetologia; 2005 Apr; 48(4):732-40. PubMed ID: 15765221
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Natural course of insulin resistance in type I diabetes.
    Yki-Järvinen H; Koivisto VA
    N Engl J Med; 1986 Jul; 315(4):224-30. PubMed ID: 3523247
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The period of initial remission in insulin-dependent diabetes. Effect of optimized insulin therapy].
    Vague P; Vialettes B; Lassmann V; Moulin JP
    Journ Annu Diabetol Hotel Dieu; 1984; ():73-84. PubMed ID: 6399541
    [No Abstract]   [Full Text] [Related]  

  • 30. Diabetes and branched-chain amino acids: What is the link?
    Bloomgarden Z
    J Diabetes; 2018 May; 10(5):350-352. PubMed ID: 29369529
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Addressing insulin resistance in Type 1 diabetes.
    Pang TT; Narendran P
    Diabet Med; 2008 Sep; 25(9):1015-24. PubMed ID: 19183305
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Intensive insulin treatment improves metabolic control and preserves residual insulin secretion at 5 years from the diagnosis of type-1 diabetes mellitus].
    Pérez Maraver M; Gonzálbez Morgaez J; Molina Lacasa A; Fernańdez Castañer M
    Med Clin (Barc); 1998 Dec; 111(19):758. PubMed ID: 9922961
    [No Abstract]   [Full Text] [Related]  

  • 33. Type 1 diabetes: benefits of intensive insulin therapy. Patients should control blood glucose strictly.
    Prescrire Int; 2002 Apr; 11(58):61. PubMed ID: 11987320
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A failure to communicate.
    Curry A
    Diabetes Forecast; 2014 Jan; 67(1):92-3. PubMed ID: 25868303
    [No Abstract]   [Full Text] [Related]  

  • 35. Disordered insulin secretion in the development of insulin resistance and Type 2 diabetes.
    Schofield CJ; Sutherland C
    Diabet Med; 2012 Aug; 29(8):972-9. PubMed ID: 22443306
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Beta-cell function and mass in type 2 diabetes.
    Larsen MO
    Dan Med Bull; 2009 Aug; 56(3):153-64. PubMed ID: 19728971
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glycaemic effects of incretins in Type 1 diabetes mellitus: a concise review, with emphasis on studies in humans.
    Dupre J
    Regul Pept; 2005 Jun; 128(2):149-57. PubMed ID: 15780434
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Brain-derived neurotrophic factor and insulin resistance during hyperinsulinaemic-euglycaemic clamp in type 1 diabetes patients in the PoProStu.
    Uruska A; Niedzwiecki P; Araszkiewicz A; Zozulinska-Ziolkiewicz D
    Diabetes Metab; 2017 Oct; 43(5):472-474. PubMed ID: 28139435
    [No Abstract]   [Full Text] [Related]  

  • 39. Insulin action and secretion in healthy, glucose tolerant first degree relatives of patients with type 2 diabetes mellitus. Influence of body weight.
    Volk A; Renn W; Overkamp D; Mehnert B; Maerker E; Jacob S; Balletshofer B; Häring HU; Rett K
    Exp Clin Endocrinol Diabetes; 1999; 107(2):140-7. PubMed ID: 10320055
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Both insulin sensitivity and insulin clearance in children and young adults with type I (insulin-dependent) diabetes vary with growth hormone concentrations and with age.
    Acerini CL; Cheetham TD; Edge JA; Dunger DB
    Diabetologia; 2000 Jan; 43(1):61-8. PubMed ID: 10663217
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.